MX2020006170A - Composiciones y metodos para prevenir y tratar afecciones. - Google Patents

Composiciones y metodos para prevenir y tratar afecciones.

Info

Publication number
MX2020006170A
MX2020006170A MX2020006170A MX2020006170A MX2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A
Authority
MX
Mexico
Prior art keywords
compositions
methods
preventing
treating conditions
treating
Prior art date
Application number
MX2020006170A
Other languages
English (en)
Inventor
Jason M Criscione
Original Assignee
Ansella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansella Therapeutics Inc filed Critical Ansella Therapeutics Inc
Publication of MX2020006170A publication Critical patent/MX2020006170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Sealing Material Composition (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Cosmetics (AREA)

Abstract

En el presente documento se proporcionan composiciones que comprenden una emulsión estable de agua en silicona, y métodos y kits que comprenden las composiciones para tratar afecciones.
MX2020006170A 2017-12-18 2018-12-14 Composiciones y metodos para prevenir y tratar afecciones. MX2020006170A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607286P 2017-12-18 2017-12-18
US201762609127P 2017-12-21 2017-12-21
PCT/US2018/065710 WO2019125945A1 (en) 2017-12-18 2018-12-14 Compositions and methods for preventing and treating conditions

Publications (1)

Publication Number Publication Date
MX2020006170A true MX2020006170A (es) 2020-11-24

Family

ID=66815467

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006170A MX2020006170A (es) 2017-12-18 2018-12-14 Composiciones y metodos para prevenir y tratar afecciones.
MX2023008764A MX2023008764A (es) 2017-12-18 2020-07-13 Composiciones y metodos para prevenir y tratar afecciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008764A MX2023008764A (es) 2017-12-18 2020-07-13 Composiciones y metodos para prevenir y tratar afecciones.

Country Status (8)

Country Link
US (2) US10668046B2 (es)
EP (1) EP3727382A4 (es)
JP (2) JP6945083B2 (es)
CN (1) CN111655262A (es)
BR (1) BR112020012195A2 (es)
CA (1) CA3086082A1 (es)
MX (2) MX2020006170A (es)
WO (1) WO2019125945A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727382A4 (en) * 2017-12-18 2021-09-08 Ansella Therapeutics, Inc. COMPOSITIONS AND METHODS OF PREVENTION AND TREATMENT OF DISEASES

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU47604A1 (es) 1964-12-17 1966-06-17
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
EP0330369A1 (en) 1988-02-16 1989-08-30 Richardson-Vicks, Inc. Skin conditioning composition
US5256422A (en) 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
FR2686510A1 (fr) * 1992-01-27 1993-07-30 Oreal Emulsion eau-dans-huile stable au cours du temps a haute teneur en silicone.
EP0738139A1 (en) 1992-03-31 1996-10-23 Alberto-Culver Company Emulsifier compositions for applying silicone oil to hair
US5304334A (en) * 1992-04-28 1994-04-19 Estee Lauder, Inc. Method of preparing a multiphase composition
DE69734498T2 (de) 1996-05-20 2006-08-10 Shiseido Co. Ltd. Oel-in-wasser emulsion und oel-in-wasser emulgator
WO1998026752A1 (en) * 1996-12-18 1998-06-25 The Procter & Gamble Company Stable high spf foundation
US6537537B2 (en) 1997-06-12 2003-03-25 The Procter & Gamble Company Water-in-silicone emulsion cosmetic compositions
US6121373A (en) 1998-10-07 2000-09-19 Dow Corning Corporation Method of making thick water-in-silicone emulsions
US6570054B1 (en) * 1999-05-21 2003-05-27 The Procter & Gamble Company Absorbent article having a stable skin care composition
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
WO2002003930A2 (en) * 2000-07-10 2002-01-17 The Procter & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
US20020022040A1 (en) * 2000-07-10 2002-02-21 The Proctor & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
JP2003104826A (ja) * 2001-09-28 2003-04-09 Kanebo Ltd Ｗ／ｏ／ｗ型複合エマルジョン
US7010494B2 (en) * 2003-03-27 2006-03-07 University Of Washington Performing predictive pricing based on historical data
DE10326899A1 (de) * 2003-06-14 2004-12-30 Beiersdorf Ag Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
US20050112078A1 (en) * 2003-11-13 2005-05-26 Sekhar Boddupalli Plant-derived protein extract compositions and methods
JP4589050B2 (ja) * 2003-12-22 2010-12-01 日本精化株式会社 ジエステル及び油剤、並びに化粧料及び皮膚外用剤
US20050222169A1 (en) * 2004-01-16 2005-10-06 Nawaz Ahmad Compositions and methods of treating infections
WO2006004759A2 (en) * 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
DE102005020583B4 (de) * 2004-09-06 2016-02-18 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Zubereitung, insbesondere kosmetische Zubereitung sowie ihre Verwendung
EP1681046A3 (de) * 2004-11-13 2008-07-30 Clariant Produkte (Deutschland) GmbH Kosmetische, pharmazeutische und dermatologische Zubereitungen enthaltend Copolymerwachse
WO2006110271A1 (en) 2005-04-07 2006-10-19 Dow Corning Corporation Water in silicone emulsions containing elastomers
CN101175503B (zh) * 2005-04-27 2012-12-12 深圳福诺生物技术有限公司 一种调节并保持***菌群和***酸度正常的组合物与方法
ITMI20060122A1 (it) * 2006-01-25 2007-07-26 Polichem Sa Composizioni per uso vaginale
EP1889654A1 (en) 2006-02-03 2008-02-20 Wockhardt Limited Silicone oil-in-water emulsions-formulation, production and use
WO2008142384A1 (en) * 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
US20090035236A1 (en) 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
WO2009135135A2 (en) * 2008-05-01 2009-11-05 Chia Soo Fibromodulin formulation for reducing corneal scarring
ES2336995B1 (es) * 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
GB0822823D0 (en) 2008-12-15 2009-01-21 Dow Corning Silicone oi-in-water emulsions
JP5940556B2 (ja) 2010-12-28 2016-06-29 ユニリーバー・ナームローゼ・ベンノートシヤープ エマルジョンの製造方法
ITRM20130199A1 (it) * 2013-04-03 2014-10-04 Irbm Science Park S P A Peptidi per uso dermatologico e/o cosmetico
EP3727382A4 (en) * 2017-12-18 2021-09-08 Ansella Therapeutics, Inc. COMPOSITIONS AND METHODS OF PREVENTION AND TREATMENT OF DISEASES

Also Published As

Publication number Publication date
CA3086082A1 (en) 2019-06-27
JP2021506956A (ja) 2021-02-22
WO2019125945A1 (en) 2019-06-27
US20200360340A1 (en) 2020-11-19
US10668046B2 (en) 2020-06-02
JP2021191791A (ja) 2021-12-16
MX2023008764A (es) 2023-08-02
JP6945083B2 (ja) 2021-10-13
CN111655262A (zh) 2020-09-11
EP3727382A1 (en) 2020-10-28
BR112020012195A2 (pt) 2020-11-24
US20190183854A1 (en) 2019-06-20
EP3727382A4 (en) 2021-09-08
JP7502242B2 (ja) 2024-06-18

Similar Documents

Publication Publication Date Title
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019007020A (es) Anticuerpos il-11.
MX2018015761A (es) Composiciones que comprenden cepas bacterianas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2019012352A (es) Composiciones, sistemas, kits y metodos para ablacion neural.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
EP3710434A4 (en) COMPOSITIONS, PROCEDURES, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MD3630136T2 (ro) Compoziții care cuprind tulpini bacteriene
GB2576614B (en) Compositions, uses and methods
MX2023006458A (es) Oligosacaridos inmunomoduladores.
MX2021006326A (es) Inhibidores de pcna.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
GB201804163D0 (en) Uses, compositions and methods
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
EP3691632A4 (en) COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases